Platinum-based chemotherapy has remained the standard of care for the treatment of platinum-sensitive ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and more recently PARP inhibitors, have entered the therapeutic landscape for this indication. Due to the regulatory approval of targeted therapies, such as Roche/Genentech’s Avastin, AstraZeneca’s Lynparza, Tesaro’s Zejula, and Clovis Oncology’s Rubraca, the market is more crowded leading to higher barriers of entry for emerging therapies in platinum-sensitive ovarian cancer. However, areas of unmet need for the treatment of platinum-sensitive ovarian cancer remain. This content evaluates the key drivers of prescribing and analyzes the areas of significant commercial opportunities that could be valuable commercial opportunities for developers.

Questions Answered:

  • What are the treatment drivers and goals for platinum-sensitive ovarian cancer?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for platinum-sensitive ovarian cancer?
  • What are the prevailing areas of unmet need and opportunity in platinum-sensitive ovarian cancer?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new therapy for platinum-sensitive ovarian cancer?

Markets covered: United States, United Kingdom, France, and Germany.

Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in April 2017.

Key companies: Roche/Genentech, AstraZeneca, Tesaro, Clovis Oncology.

Key drugs: Carboplatin/Paclitaxel, Avastin, Lynparza, Zejula, Rubraca.

Table of contents

  • Detailed, Expanded Analysis (US/EU)
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Nonclinical Attributes
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Physician Rating of Treatment Drivers and Goals in Platinum-Sensitive Ovarian Cancer
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Stated vs. Derived Importance of Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Unmet Need in Platinum-Sensitive Ovarian Cancer and Related Indications
      • Physician Rating of Unmet Need in Platinum-Sensitive Ovarian Cancer
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
    • Opportunity Analysis
      • Areas of Opportunity in the Platinum-Sensitive Ovarian Cancer Market and Emerging Therapy Insights
        • Opportunity: A New Therapy with Prolonged Overall Survival
        • Opportunity: A New Therapy with Lower Incidence of Severe Neurotoxicity
        • Opportunity: A New Therapy with Lower Incidence of Severe Hematological Toxicity
        • Opportunity: A Novel Biomarker Predictive of Response to Therapy
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Platinum-Sensitive Ovarian Cancer Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Experts Interviewed
      • Bibliography

Author(s): Carolina do Pazo, M.Sc

Carolina do Pazo, is a Business Insights Analyst in the oncology division at Decision Resources Group. Prior to joining DRG, she completed a MSc in Biotechnology, Bioprocessing and Business Management with distinction at the University of Warwick, as a Chevening scholar. She also earned her first-class BSc and BEng in Biotechnology from the Universidad ORT. Ms. do Pazo has worked as a Research Scientist at the Institut Pasteur de Montevideo, analysing the ageing process of yeast cells, and has been part of a project between Indiana University and Universidad ORT that analysed the production of nanohybrids for drug delivery systems applications.


Related Reports

Ovarian Cancer | Landscape & Forecast | Disease Landscape & Forecast

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care for ovarian cancer; however, treatment is moving toward a targeted approac...

View Details

Ovarian Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU5)

Market Outlook Targeted therapies are changing the treatment paradigm for ovarian cancer in the top 5 European markets (France, Germany, Italy, Spain, UK). Roche’s...

View Details

Ovarian Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Chemotherapy remains the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently,

View Details

Ovarian Cancer | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details